dothedd
Senior Member
Joined: Dec 27, 2010 20:43:28 GMT -5
Posts: 2,683
|
Post by dothedd on Feb 15, 2011 13:52:05 GMT -5
A Phase 2 Study to Assess the Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine
This study is ongoing, but not recruiting participants.
First Received: February 19, 2010 Last Updated: March 8, 2010 History of Changes
Sponsor: Novavax
Collaborator: Instituto Mexicano del Seguro Social
Information provided by: Novavax
ClinicalTrials.gov Identifier: NCT01072799 clinicaltrials.gov/ct2/show/NCT01072799?term=novavax&rank=5
|
|
dothedd
Senior Member
Joined: Dec 27, 2010 20:43:28 GMT -5
Posts: 2,683
|
Post by dothedd on Feb 15, 2011 14:30:50 GMT -5
Tracking Information
First Received Date ICMJE February 19, 2010
Last Updated Date March 8, 2010
Start Date ICMJE October 2009
Estimated Primary Completion Date October 2010 (final data collection date for primary outcome measure)
Current Primary Outcome Measures ICMJE
(submitted: February 19, 2010) •Adverse Events [ Time Frame: 0-21 days ] [ Designated as safety issue: Yes ]
•Serious Adverse Events [ Time Frame: 6 Months ] [ Designated as safety issue: Yes ]
•Immunogenicity by HAI [ Time Frame: 14 days ] [ Designated as safety issue: No ]
Original Primary Outcome Measures ICMJE Same as current
Change History Complete list of historical versions of study NCT01072799 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ICMJE
CONTINUED:
clinicaltrials.gov/ct2/show/record/NCT01072799?term=novavax |
|
